ArticlePhysiological reports2026
A comparison of plasma Tsukushi in adolescents with and without metabolic dysfunction-associated steatotic liver disease.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease in children and adolescents. Assessment of circulating biomarkers is needed to understand the underlying pathology, disease severity, and treatment options. The secreted hepatokine Tsukushi (TSK) is involved in lipid and carbohydrate metabolism. TSK is increased in adults with MASLD but has yet to be reported in adolescents. We hypothesized that plasma TSK is increased in adolescents with MASLD compared to peers without MASLD classified as obese (Ob) or normal weight (NW). We tested adolescents 10-20 years old with obesity and biopsy-confirmed MASLD (17F, 46 M), and controls without MASLD with either Ob (16F, 16 M) or NW (15F, 20 M). Fasting plasma TSK concentration was 27% higher (p < 0.05) in the MASLD group (median [interquartile range]: 188 [120, 418] ng/mL) than the NW group (148 [80, 241]), while the Ob group was intermediate (165 [84, 466]) and not different from the other two groups. TSK did not differ across histological grades of steatosis or fibrosis. Although TSK was increased in the MASLD group compared to NW controls, the lack of difference in TSK between the Ob and MASLD groups limits its value as a potential biomarker for MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.